ETERN Therapeutics Announces Completion of Series B Financing to Advance the Protein Liquid-Liquid Phase Separation Technology Platform and Accelerate the Development of Novel Drugs to Target "Undruggable" Proteins
Summary
Proceeds from this financing are anticipated to be used to enhance the Protein Liquid-Liquid Phase Separation (LLPS) technology platform and advance multiple pipelines through discovery and clinical development.ETERN, established in October 2018, was co-founded by Dr. Jidong Zhu, formerly a professor in the "Hundred Talents Program" at the Chinese Academy of Sciences. Based on the teams rich drug development experience, ETERN has built a solid pipeline of innovative products from its LLPS technology platform for "undruggable" targets, including transcription factors and phosphatases. Based on years of basic research, ETERN has built an innovative LLPS technology platform to effectively target the "undruggable" proteins and solve major global unmet medical needs. With the world-leading Protein Liquid-Liquid Phase Separation (LLPS) technology platform, ETERN has built multiple pipelines and advanced one to the clinical stage to provide new solutions to cancer patients. Since its establishment, Morningside has been focusing on trends of the forefront life science and healthcare industries over the world, spreading its business scope and investment footprint over North American, Europe and Greater China.